FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a method for preparing a milk thistle extract having a higher degree of silymarin release. A method for preparing a milk thistle extract, wherein the extract containing 15-85 wt %, particularly 30-65 wt % of silymarin is treated with anhydrous C1-C4 alcohol, optionally filtered and concentrated, then dried and optionally ground, wherein a degree of silymarin release is 80% or higher (versions). The milk thistle extract for treating and preventing liver and gallbladder dysfunctions. A pharmaceutical composition for treating and preventing liver and gallbladder dysfunctions.
EFFECT: extract is characterised by a higher degree of silymarin release and effective for treating and preventing the liver and gallbladder dysfunctions.
8 cl, 3 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FLAVANE-LIGNAN COMPOSITION AND DRUG BASED ON THEREOF | 1996 |
|
RU2157225C2 |
| COMPOSITIONS CONTAINING SULFORAPHANE OR SULFORAPHANE PRECURSOR AND EXTRACT OR POWDER OF MILK THISTLE | 2013 |
|
RU2785683C2 |
| COMPOSITIONS COMPRISING A SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND MILK THISTLE EXTRACT OR POWDER | 2013 |
|
RU2666953C2 |
| USE OF FLAVANOLIGNANS AS DRUGS SHOWING ANTIPROLIFERATIVE ACTIVITY WITH RESPECT TO TUMORS OF UTERUS, OVARY AND MAMMARY GLAND | 1995 |
|
RU2161488C2 |
| SILIBILIN COMPONENT FOR TREATING HEPATITIS | 2008 |
|
RU2482844C2 |
| SOLID MEDICINAL FORMULATION OF HEPATOPROTECTIVE EFFECT | 2006 |
|
RU2314797C2 |
| HEPATOPROTECTIVE AND ANTIHEPATOTOXIC PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING HEPATIC DISEASES THAT INVOLVES INTRODUCTION OF SAID COMPOSITION | 2008 |
|
RU2381800C1 |
| COMBINED AGENT CONTAINING UDCA, HYMECROMONE AND SILYMARIN (VERSIONS) | 2017 |
|
RU2738444C2 |
| COMPOSITION FOR THERAPY OF HEPATIC PATHOLOGIES AND ONCOLOGICAL DISEASES | 2008 |
|
RU2379046C1 |
| METHOD OF PRODUCING A POLYMER-CONTAINING SILYBIN COMPOSITION | 2019 |
|
RU2716706C1 |
